Spruce Biosciences (NASDAQ:SPRB – Get Free Report) and Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Profitability
This table compares Spruce Biosciences and Whitehawk Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spruce Biosciences | N/A | -155.40% | -101.67% |
| Whitehawk Therapeutics | N/A | -79.63% | -74.01% |
Institutional and Insider Ownership
91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spruce Biosciences | $4.91 million | 28.63 | -$38.97 million | ($36.60) | -1.40 |
| Whitehawk Therapeutics | N/A | N/A | -$20.60 million | ($1.68) | -2.57 |
Whitehawk Therapeutics has lower revenue, but higher earnings than Spruce Biosciences. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Spruce Biosciences has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Spruce Biosciences and Whitehawk Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spruce Biosciences | 1 | 2 | 7 | 0 | 2.60 |
| Whitehawk Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Spruce Biosciences presently has a consensus price target of $163.00, suggesting a potential upside of 218.86%. Whitehawk Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 69.83%. Given Spruce Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Spruce Biosciences is more favorable than Whitehawk Therapeutics.
Summary
Spruce Biosciences beats Whitehawk Therapeutics on 7 of the 12 factors compared between the two stocks.
About Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
